Adverse effects were few: weight gain and fluid retention were evident in five patients when captopril was introduced and two patients initially experienced mild postural dizziness; rashes in two patients did not recur when the drug was reintroduced at a lower dose; there was a significant reduction in white cell count overall, but the lowest individual white cell count was 4000x 106/1.
Severe congestive cardiac failure entails a heavy burden of symptoms and carries a grave prognosis. Although mortality is proportional to the extent of depression of cardiac function, many patients do not die with steadily progressive heart failurel 2 and are often presumed to have succumbed to arrhythmias. Vasodilator drugs can increase cardiac performance, but there is little evidence that they improve prognosis.3 4 Captopril would be expected to have all the advantageous properties of conventional vasodilators in severe heart failure and also to have substantial additional benefits. Converting enzyme inhibition should overcome the possibly adverse direct renal effects of the renin-angiotensin system in severe heart failure as Requests for reprints to Dr J G F Cleland, Department of Cardiology, Western Infirmary, Glasgow GIl 6NT.
Accepted for publication 17 July 1984 well as lowering secretion of antidiuretic hormone and aldosterone. 5 Several open studies have indicated benefit from treatment with captopril6-8; a double blind trial is, however, critical in assessing the long term effect of any drug in a disease with such prominent symptoms and fluctuating natural history. Three controlled studies of captopril have all shown distinct improvement in exercise tolerance and dyspnoea.9-"l We report a double blind controlled trial of prolonged treatment with captopril in patients with severe congestive heart failure. In addition to evaluating symptoms, we measured body sodium and potassium contents and recorded 24 hour ambulatory electrocardiograms. (Preliminary reports of some parts of this study have already been made. 12 13) Patients and methods Fourteen men and six women (mean age 62 years) with severe congestive heart failure (New York Heart (ml1min)  1  3  2   0   7   2  3  25  4  14   3  3  3  8  21   4  3  3  12  28  5  3  3  16  33  6  3  3  20  39 Association classes III or IV) of more than six months' duration were studied. Thirteen had ischaemic heart disease, four congestive cardiomyopathy, and three severe left ventricular dysfunction associated with valvar regurgitation. All were receiving digoxin together with frusemide (mean dose 375 mg/day); three were also receiving bendrofluazide 5 mg daily, and two others had been taking amiodarone 200 mg daily for more than a year. Six patients had atrial fibrillation. None had angina, significant respiratory disease, or serum creatinine concentrations >200
,umol/l (2.26 mg/100 ml). All gave written consent to the trial, which was approved by the hospital's ethical supervisory committee.
The study was in four phases, full patient assessment being performed at the end of each. Firstly, during a run in phase of two weeks, treatment with digoxin, diuretics, potassium supplements, and amiodarone was stabilised and the patient made familiar with the procedures, including treadmill exercise. Secondly, captopril was introduced at a dose of 6-25 mg three times daily and titrated to a fixed thrice daily dose for each patient and 1600 with a standard sphygmomanometer lying and after two minutes' standing; heart rate was recorded at the same times. Total body potassium content was measured from endogenous potassium-40, using the whole body counter; total body sodium content was measured similarly after activation analysis. '9-22 Renal plasma flow and glomerular filtration rate were estimated with radioisotope clearance methods, using sodium iodohippurate (3l'I) and technetium-99m diethylenetriamine penta-acetic acid.2324 Urinary creatinine clearance over 24 hours was also measured.
STATISTICAL METHODS
The results of three analyses are presented, each based on standard statistical methods with the data transformed to a logarithmic scale as appropriate. The first comparison was between the start and finish for the open study and the second between the ends of the phases of the double blind study . during which placebo or captopril was given. The final comparison used repeated measures analyses of variance to incorporate data from the start of the double blind study together with data from the end of the placebo and captopril phases, and in effect this compared the changes during the two double blind six week periods of treatment. The design of the study shows that this final analysis would be sensitive to any effect of the order of treatment allocation, and the results are not reported in cases where the order effect was significant at the 5% level.
Results Table 2 gives the results of all the tests undertaken.
Clinical outcome-Of the 20 patients entered, 14 completed the study. Two died in the initial run in phase, two during the open captopril phase, and one in the double blind phase while taking placebo. The condition of a sixth patient with mitral incompetence improved considerably during the open captopril phase, and he was therefore withdrawn for valve replacement. 48 (25) 26 (20) 12 (14) 28 (28) p<0-04 p<0-02
Ankle swelling (mm)
20 (25) 6 (7) 6 (8) 8 (14) p<0-04 NS Supine heart rate (beats/minute) 83 (9) 79 (10) 75 (11) 79 (11) p<0-05 NS Supine systolic blood pressure (mm Hg) 118 (20) 109 (16) 110 (18) 130(27) p<O-0l p<0-001
Supine diastolic blood pressure (mm Hg) 79 (14) 68 (12) 64 (13) 83 (16) p<0O01 p<0-001
Standing heart rate (beats/minute)
88 (12) 83 (10) 82 (13) 85 (14) p<0-05
NS
Standing systolic blood pressure (mm Hg) 115 (26) 102 (14) 112 (17) 127(26) p<0O01 -p<0-005
Standing diastolic blood pressure (mm Hg) 77 (21) 71 (15) 72 (15) (15) 0 (16) p<0-03 -12 (11) +5(12) p<0Ol +0-2(1.1) Blood pressure and heart rate-Both systolic and diastolic pressures, supine and standing, were lower during treatment with captopril; there was no postural fall in blood pressure. Heart rate was not significantly changed in either posture (Table 2) .
Weight-With the initiation of captopril in the open phase, mean (SD) body weight rose over the first week from 66.3(2.5) kg to 67.5(2-6) kg (n= 18; p<005). This was largely due to distinct retention of fluid in five patients, two of whom required an increase in frusemide dosage. There were thereafter no significant differences in body weight between the mean values at the end of each phase of the study (Table 2) .
Symptoms-Breathlessness, tiredness, and New York Heart Association classification were all significantly improved in the double blind captopril phase of the study; by contrast, ankle swelling was not.
Exercise testing-Exercise time was significantly increased during double blind captopril treatment ( 
Discussion
The present double blind study showed clear symptomatic benefit of treatment with captopril in congestive heart failure, with prolongation of exercise time and reduced dyspnoea. These present findings confirm the symptomatic improvement reported with captopril in the two previous double blind trials.9 10 In our study, echocardiography showed reduction in both end systolic The present trial showed clearly that the use of captopril in the treatment of severe cardiac failure corrects many biochemical anomalies, limits arrhythmias, improves cardiac performance, and benefits patients symptomatically. Although several of these aspects would be expected also to improve prognosis, this remains to be confirmed.
